Rua Bioscience Limited (NZE:RUA)

New Zealand · Delayed Price · Currency is NZD

0.0300

-0.0010 (-3.23%)

Apr 28, 2026, 4:12 PM NZST

20.00% (1Y)

Market Cap	10.14M
Revenue (ttm)	2.39M
Net Income (ttm)	-3.45M
Shares Out	338.04M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,352
Average Volume	39,140
Open	0.0310
Previous Close	0.0310
Day's Range	0.0300 - 0.0310
52-Week Range	0.0230 - 0.0590
Beta	0.50
RSI	26.59
Earnings Date	May 28, 2026

About Rua Bioscience

Rua Bioscience Limited engages in the research, development, and sale of pharmaceutical products in New Zealand and internationally. It offers cannabis-derived medicines. The company is also involved in seed production and genetic discovery related activities. In addition, it engages in plant breeding business, as well as involved in plant research activities. Rua Bioscience Limited was formerly known as Hikurangi Cannabis Company Limited and changed its name to Rua Bioscience Limited in October 2019. The company was founded in 2016 and is base... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2016

Country New Zealand

Stock Exchange New Zealand Stock Exchange

Ticker Symbol RUA

Full Company Profile

Financial Performance

In fiscal year 2025, Rua Bioscience's revenue was 1.83 million, an increase of 477.39% compared to the previous year's 316,350. Losses were -3.46 million, -74.81% less than in 2024.

Financial Statements

News

Rua Bioscience Transcript: AGM 2025

The meeting highlighted strong revenue growth, reduced losses, and expansion into five markets, while emphasizing the need for a NZD 2 million capital raise and the sale of a manufacturing facility to support ongoing operations. All resolutions were supported, and the board remains focused on cost control and strategic growth.

6 months ago - Transcripts

Rua Bioscience Transcript: AGM 2024

The meeting reviewed a year of strategic refocus, international expansion, and financial challenges, with significant sales growth in early FY25. Shareholders approved resolutions on auditor remuneration and new share issuance, while management addressed liquidity, market competitiveness, and future growth plans.

1 year ago - Transcripts